000908 Stock Overview
Manufactures and sells chemical drugs and biological agents in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hunan Jingfeng Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.90 |
| 52 Week High | CN¥6.36 |
| 52 Week Low | CN¥0.72 |
| Beta | 0.45 |
| 1 Month Change | -2.78% |
| 3 Month Change | 36.49% |
| 1 Year Change | 51.23% |
| 3 Year Change | 12.39% |
| 5 Year Change | 25.96% |
| Change since IPO | -56.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 000908 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 12.4% | -1.9% | -0.6% |
| 1Y | 51.2% | -5.7% | 8.3% |
Return vs Industry: 000908 exceeded the CN Pharmaceuticals industry which returned -5.4% over the past year.
Return vs Market: 000908 exceeded the CN Market which returned 9.2% over the past year.
Price Volatility
| 000908 volatility | |
|---|---|
| 000908 Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.9% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 000908 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000908's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 572 | Xiang Wu Ye | www.jfzhiyao.com |
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company’s principal product is sodium hyaluronate injection for use in orthopedics and surgery applications.
Hunan Jingfeng Pharmaceutical Co.,Ltd. Fundamentals Summary
| 000908 fundamental statistics | |
|---|---|
| Market cap | CN¥4.31b |
| Earnings (TTM) | -CN¥286.00m |
| Revenue (TTM) | CN¥397.76m |
10.8x
P/S Ratio-15.1x
P/E RatioIs 000908 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000908 income statement (TTM) | |
|---|---|
| Revenue | CN¥397.76m |
| Cost of Revenue | CN¥180.67m |
| Gross Profit | CN¥217.09m |
| Other Expenses | CN¥503.10m |
| Earnings | -CN¥286.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 54.58% |
| Net Profit Margin | -71.90% |
| Debt/Equity Ratio | -218.0% |
How did 000908 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 07:04 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Jingfeng Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guohe Fan | Phillip Securities (HK) |
| Yin Ye | Ping An Securities Co. Ltd. |